复星医药：复迈宁新适应症上市申请获优先审评受理

财中社02-05

2月5日，复星医药（600196/02196）发布公告，控股子公司药品注册申请获受理。　　公司控股子公司上海复星医药产业发展有限公司自主研发的复迈宁®（通用名：芦沃美替尼片）用于治疗伴有症状、无法手术的丛状神经纤维瘤的Ⅰ型神经纤维瘤病成人患者的药品上市申请已获国家药品监督管理局受理，并被纳入优先审评程序。　　截至2025年12月，针对该药品的累计研发投入约为6.63亿元。根据IQVIAMIDAS...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2609432214?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-05 16:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609432214","market":"us","top_or_hot":-1,"title":"复星医药：复迈宁新适应症上市申请获优先审评受理","media":"财中社","content":"<div>\n<p>2月5日，复星医药（600196/02196）发布公告，控股子公司药品注册申请获受理。　　公司控股子公司上海复星医药产业发展有限公司自主研发的复迈宁®（通用名：芦沃美替尼片）用于治疗伴有症状、无法手术的丛状神经纤维瘤的Ⅰ型神经纤维瘤病成人患者的药品上市申请已获国家药品监督管理局受理，并被纳入优先审评程序。　　截至2025年12月，针对该药品的累计研发投入约为6.63亿元。根据IQVIAMIDAS...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202602053642780133.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复星医药：复迈宁新适应症上市申请获优先审评受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复星医药：复迈宁新适应症上市申请获优先审评受理\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-05 16:43 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202602053642780133.html><strong>财中社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2月5日，复星医药（600196/02196）发布公告，控股子公司药品注册申请获受理。　　公司控股子公司上海复星医药产业发展有限公司自主研发的复迈宁®（通用名：芦沃美替尼片）用于治疗伴有症状、无法手术的丛状神经纤维瘤的Ⅰ型神经纤维瘤病成人患者的药品上市申请已获国家药品监督管理局受理，并被纳入优先审评程序。　　截至2025年12月，针对该药品的累计研发投入约为6.63亿元。根据IQVIAMIDAS...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202602053642780133.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0187","symbol_name":"一线龙头","start_time":0,"source_url":"http://finance.eastmoney.com/a/202602053642780133.html","article_id":"2609432214","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609432214","pubTimestamp":1770280995,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"2月5日，复星医药（600196/02196）发布公告，控股子公司药品注册申请获受理。公司控股子公司上海复星医药产业发展有限公司自主研发的复迈宁?（通用名：芦沃美替尼片）用于治疗伴有症状、无法手术的丛状神经纤维瘤的Ⅰ型神经纤维瘤病成人患者的药品上市申请已获国家药品监督管理局受理，并被纳入优先审评程序。截至2025年12月，针对该药品的累计研发投入约为6.63亿元。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600196":"复星医药","BK0187":"一线龙头","BK0175":"白马股","BK0060":"抗癌","BK0028":"国家队","BK0239":"医药制造","02196":"复星医药","BK0183":"MSCI概念","BK1191":"制药","BK0188":"融资融券","BK1515":"抗疫概念","BK0096":"民营医院","BK0012":"证金概念","BK1593":"医美概念股","BK0196":"行业龙头"},"translate_title":"Fosun Pharma: Fumaining's new indication marketing application was accepted for priority review","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1.5,"02196":1.5},"content_text":"2月5日，复星医药（600196/02196）发布公告，控股子公司药品注册申请获受理。　　公司控股子公司上海复星医药产业发展有限公司自主研发的复迈宁®（通用名：芦沃美替尼片）用于治疗伴有症状、无法手术的丛状神经纤维瘤的Ⅰ型神经纤维瘤病成人患者的药品上市申请已获国家药品监督管理局受理，并被纳入优先审评程序。　　截至2025年12月，针对该药品的累计研发投入约为6.63亿元。根据IQVIAMIDAS最新数据，2024年，MEK1/2选择性抑制剂于全球范围的销售额约为20.68亿美元。　　公司提醒，新增适应症在开展商业化前尚需获得药品注册批准，获药品注册申请受理不会对公司现阶段业绩产生重大影响。　　2025年前三季度，复星医药实现收入293.93亿元，归母净利润25.23亿元。（文章来源：财中社）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2609432214","isCrawlerRequest":true}